Capstan Therapeutics

Capstan Therapeutics is a biotechnology company focused on advancing in vivo cell reprogramming through RNA delivery using targeted lipid nanoparticles (tLNP). Its core platform technology aims to create transformative therapies for various diseases by delivering payloads to reprogram specific cell types within the body. This approach offers potential applications across autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.


Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $175M

Date: 20-Mar-2024

Investors: RA Capital Management, Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures

Markets: Biotechnology, RNA Therapeutics, Immunology, Oncology, Autoimmune Disorders

HQ: San Diego, California, United States

Founded: 2021

Website: https://www.capstantx.com

LinkedIn: https://www.linkedin.com/company/capstan-therapeutics/

Twitter: https://twitter.com/capstantx

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/capstan-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/495497-62


Leave a Comment